The Muscle Peptide Evidence Gap: What the Trials Actually Show

The pitch is always the same: a peptide, injected or dosed under the tongue, promises what protein shakes and hard training supposedly can’t deliver. The scientific record tells a more modest story. Across the compounds most commonly marketed for muscle growth, researchers have documented hormone spikes, animal studies, and one disease-population trial. What’s largely missing is proof that any of it makes a healthy adult stronger. That gap, between what a compound does to a hormone panel and what it does to actual muscle function, is the organizing fact of this whole category, and it’s worth walking through compound by compound before getting to the harder question of where and whether to obtain one.

The best-studied compound sets the ceiling, not the floor

Ibutamoren, known by its research name MK-677, has more human data behind it than any other muscle peptide on the market. That makes its best trial worth reading closely. In a two-year randomized, placebo-controlled study of healthy older adults, researchers reported that MK-677 raised growth hormone and IGF-1 and increased fat-free mass by about 1.1 kg, versus a loss of roughly 0.5 kg in the placebo group. The mechanism is straightforward: MK-677 mimics ghrelin, prompting the pituitary to release more growth hormone, which in turn drives IGF-1 production.

The catch is in the trial’s own language. The investigators noted that the increase in fat-free mass “did not result in changes in strength or function” [1]. In other words, the most rigorously tested compound in this space added a small amount of mass, some of it non-contractile tissue and fluid, without producing a measurable functional benefit. That’s not a reason to dismiss the category outright, but it is the evidentiary ceiling. Anyone claiming a peptide will reliably build usable strength is already exceeding what the best-controlled trial found.

The hormone-releasing peptides: real signals, unproven endpoints

CJC-1295, hexarelin, GHRP-6 and ipamorelin belong to a family of growth hormone secretagogues, compounds that stimulate the pituitary through slightly different receptor pathways. The pharmacology is well documented. In healthy adults, CJC-1295 raised growth hormone 2- to 10-fold and IGF-1 1.5- to 3-fold, with effects persisting for days [2]. Hexarelin produced roughly double the growth hormone response of growth-hormone-releasing hormone alone [5], and GHRP-6-class peptides showed an even larger combined response when paired with GHRH [3]. Ipamorelin, notably, achieved a GH increase without the cortisol and prolactin elevation seen with older secretagogues, which is why researchers described it as the first selective compound of its kind [4].

All of this is hormone data. None of the cited trials measured lean mass, strength, or physical function as an endpoint. A higher IGF-1 reading is the mechanism researchers hope drives growth, not confirmation that it happened. The honest summary: these compounds reliably move blood markers, and no published human trial has shown that movement translates into muscle a healthy adult can use.

Follistatin’s animal data doesn’t transfer cleanly to the human trial that exists

Follistatin blocks myostatin, a protein that normally restrains muscle growth, and in animal models that blockade produces dramatic size increases. But the human evidence doesn’t come from healthy volunteers. It comes from a phase 1/2a gene therapy trial in Becker muscular dystrophy, a muscle-wasting disease, in which a gene-transfer construct delivered into muscle tissue improved six-minute walk distance in some patients [5b].

That’s a meaningful result, for a specific disease population, delivered through gene therapy rather than an injectable peptide. There is no approved follistatin therapy, and no evidence bridges that gene-therapy result to what happens when a healthy adult injects a compounded follistatin peptide. The animal photographs and the human trial answer two different questions.

IGF-1 LR3: the most direct mechanism, and the compound with an actual safety signal attached

IGF-1 LR3 is an engineered analog of IGF-1 designed to resist the proteins that normally clear it from circulation, which theoretically makes it the most direct muscle-growth signal available. In practice, controlled human trials measuring muscle outcomes are essentially absent. What does exist is a large prospective cohort study, nearly 400,000 participants, that found higher circulating IGF-1 associated with increased risk of several cancers, including breast and prostate [6]. Deliberately elevating a growth signal that a large study has already linked to cancer risk, using an analog engineered to evade the body’s own regulatory brakes, is a materially different proposition than the other compounds discussed here. This is the one where clinical oversight matters most.

What follows from a thin evidence base

Laid side by side, these compounds occupy roughly the same evidentiary tier: they alter hormones or perform in animal models, but none has demonstrated muscle growth with functional benefit in a controlled human trial, and none is FDA-approved for this use. Given that, the more consequential variable isn’t which molecule someone picks. It’s whether a clinician reviewed bloodwork and history beforehand, whether a licensed pharmacy produced the product, and whether anyone is monitoring for adverse effects afterward. That shifts the practical question from pharmacology to sourcing.

Where the sourcing question actually lands

Among telehealth options offering physician-supervised access to this category, FormBlends is the strongest fit, for the same reason the evidence review above matters: a licensed physician reviews the patient’s profile before anything is prescribed, and the compounded product is prepared by licensed 503A pharmacies operating under USP standards. The service covers IGF-1 LR3, follistatin 344, MK-677, ipamorelin, CJC-1295, GHRP-6, and hexarelin, along with related secretagogues like sermorelin, tesamorelin, and GHRP-2. What separates this from an unregulated chemical vendor isn’t the molecule itself, it’s that a prescriber and a licensed pharmacy stand between the patient and the vial.

FormBlends also states plainly that its compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality, and that prescribing decisions rest on the provider’s independent clinical judgment. Given how limited the trial data is for this entire category, that disclosure is the right posture. Patients who proceed can use a tracking tool such as the FormBlends tracker app to log doses and symptoms for review with their clinician. It functions as a record-keeping aid, not a storefront.

HealthRX.com runs a comparable model, clinician review, prescription, licensed pharmacy dispensing, the same regulatory disclosure, plus ongoing monitoring, and is the reasonable second choice in this supervised tier. Which of the two a patient chooses generally comes down to state licensing and which platform supports the specific compound their clinician approves.

The alternative, research-chemical vendors selling peptides labeled “for research use only, not for human consumption,” operates on different footing entirely. That label isn’t boilerplate; it’s the legal basis the product is sold under, meaning no clinician evaluates the buyer and no pharmacy stands behind the formulation. Several such sellers are visible in this market:

• Swiss Chems sells research peptides and SARMs for laboratory use with seller-supplied documentation. No clinician, no pharmacy, no recall authority.
• Pure Rawz operates a broad research-chemical catalog, with some seller-provided testing, but the same structural gaps.
• Sports Technology Labs publishes third-party certificates of analysis, a genuine point of distinction, though the products remain research-use-only with no prescriber or sterile-compounding guarantee behind them.
• Biotech Peptides sells research-grade peptides with seller documentation, again absent any pharmacy or prescriber oversight.

None of these vendors can be meaningfully ranked against each other from the outside; purity and dosing accuracy aren’t independently verifiable in the way a licensed pharmacy’s are. In a category where at least one compound has a documented association with cancer risk in a large cohort study [6], “the seller posted a certificate” is a lower bar than clinical accountability.

Legal status and competitive sport are separate questions

None of the seven compounds discussed is an FDA-approved drug for building muscle. Some exist as compounded formulations of an established ingredient not reviewed by the FDA in that form; others are sold in the research-chemical gray zone, legally marketed for laboratory use while being unapproved for the human use most buyers actually intend.

Competitive sport is a separate and stricter matter. Under the 2026 WADA Prohibited List, growth hormone secretagogues including MK-677 and ipamorelin, GH-releasing peptides including GHRP-6 and hexarelin, and IGF-1 with its analogues are prohibited at all times, in and out of competition, regardless of dose or route [7][8]. Follistatin-mediated myostatin inhibition falls under the same prohibition. A “research use only” label provides no protection to a tested athlete. Anyone competing in a drug-tested sport should treat this entire category as off-limits absent explicit clearance from a sports physician.

What people tend to ask

What are peptides for muscle growth, exactly?

They are short chains of amino acids that prompt the body to release hormones or growth factors involved in building muscle tissue. The best-studied ones work by triggering growth hormone release or by mimicking insulin-like growth factor activity. They are not protein supplements, and most occupy a regulatory gray zone: developed for research purposes, not approved as drugs for everyday use in healthy people.

Which peptide has the strongest evidence for muscle growth?

BPC-157 and IGF-1 LR3 attract considerable attention online, but the clinical evidence for either in healthy humans is thin. CJC-1295 and ipamorelin have more pharmacokinetic data documenting growth hormone elevation, though whether that elevation produces measurable muscle gains in trials remains unconfirmed. Sermorelin has the longest history of medical use. The honest summary is that no single peptide has robust, replicated human trial data demonstrating muscle-building outcomes.

Are these peptides safe?

Safety depends on the specific compound, dose, individual health status, and where the product came from. Some growth hormone secretagogues have shown reasonable short-term safety profiles in supervised clinical settings. For most buyers, the larger risk is product quality: research-chemical suppliers operate without regulatory oversight, so purity and concentration are frequently unreliable. Physician-supervised compounding pharmacies, such as those FormBlends works with, operate under a materially different standard than the unregulated research-chemical market.

Where should someone buy these, and what are the actual risks?

Most peptides marketed for muscle growth are sold as research chemicals, meaning there’s no regulatory oversight of purity, sterility, or label accuracy. Independent testing of such products has repeatedly turned up dosing errors and contamination. Buying through unregulated vendors carries real health risk, not just a financial one. The route with actual quality control and accountability runs through a licensed prescriber and a compounding pharmacy, a path that narrows the options but adds a layer of oversight the research-chemical market simply doesn’t have.

References

1. Nass R, Pezzoli SS, Oliveri MC, et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.” Ann Intern Med. 2008;149(9):601-611. PMID 18981485. https://pubmed.ncbi.nlm.nih.gov/18981485/ (MK-677 increased fat-free mass +1.1 kg vs -0.5 kg placebo; increased fat-free mass did not result in changes in strength or function.)
2. Teichman SL, Neale A, Lawrence B, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/ (CJC-1295 raised GH 2- to 10-fold and IGF-1 1.5- to 3-fold; investigational.)
3. Giustina A, Bussi AR, Deghenghi R, et al. “Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess.” J Endocrinol. 1995;146(2):227-232. PMID 7561633. (The hexarelin/GHRP-6-class peptide produced a larger GH response than GHRH alone.)
4. Raun K, Hansen BS, Johansen NL, et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998;139(5):552-561. PMID 9849822. (Ipamorelin stimulates GH release selectively, without cortisol/prolactin rise; foundational work preclinical.)
5. Ghigo E, Arvat E, Gianotti L, et al. “Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.” J Clin Endocrinol Metab. 1994;78(3):693-698. PMID 8126144. (Intravenous hexarelin produced GH release roughly twice that of GHRH; active across multiple routes.) 5b. Mendell JR, Sahenk Z, Malik V, et al. “A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.” Mol Ther. 2015;23(1):192-201. PMID 25322757. (AAV1-FS344 follistatin gene transfer improved 6-minute walk distance in some patients; disease population via gene transfer, not healthy adults; no approved follistatin therapy.)
6. Knuppel A, Fensom GK, Watts EL, et al. “Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK Biobank.” Cancer Res. 2020;80(18):4014-4021. PMID 32709735. (Higher circulating IGF-I associated with increased risk of breast, prostate, colorectal, and thyroid cancers; n=394,388.)
7. WADA 2026 Prohibited List, S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics, prohibited at all times. Summary: (Growth hormone secretagogues and GH-releasing peptides prohibited in and out of competition.)
8. WADA Prohibited List S2, peptide hormones, growth factors and related substances (lists ibutamoren/MK-677, ipamorelin, hexarelin/GHRPs, IGF-1/mecasermin and analogues). (Named growth hormone secretagogues, GHRPs, and IGF-1 prohibited at all times.)